Navigation Links
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
Date:11/6/2008

velopment for the treatment of SHPT in CKD patients undergoing dialysis. In Phase I, CTA018 Injection was well tolerated and produced clinically meaningful reductions in blood levels of PTH after less than two weeks of administration. No clinically relevant elevations in serum calcium or phosphorus were observed.

Cytochroma has granted Mitsubishi Tanabe Pharma Corporation (MTPC) exclusive rights to CTA018 in the U.S. and Asia. The companies have a co-development and co-promotion partnership in the U.S., whereas in Asia, MTPC has sole responsibility for development and commercialization in exchange for royalties.

About CTA018

CTA018 is the first compound in a new class of vitamin D hormone analogs having a novel dual mechanism of action. CTA018 is designed to be a strong activator of the vitamin D signaling pathway as well as a potent inhibitor of CYP24, the intracellular cytochrome P450 enzyme responsible for inactivation of vitamin D hormones. Based on its mechanism of action, CTA018 is expected to be safer and more effective in treating SHPT than currently available therapies. CTA018 was designed by Professor Gary H. Posner, Ph.D. and is protected under patents and patent applications exclusively licensed to Cytochroma from the Johns Hopkins University.

About Chronic Kidney Disease

According to the National Kidney Foundation, more than eight million patients in the U.S. suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5). Stages 3 and 4 are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is minimal to altogether absent and patients require regular dialysis or a kidney transplant for survival. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Mounting evidence continues to link vitamin D insufficiency with progression of CKD and death. CKD is caused most fre
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Nocturia ... as the complaint that the individual has to ... voiding. The report “Nocturia – Pipeline Review, H2 ... for Nocturia, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:11/22/2014)... 22, 2014 (HealthDay News) -- The wide variety and ... a threat for people with food allergies, an expert ... so many types of food allergies that it can ... holidays," Dr. Guha Krishnaswamy, director of allergy and clinical ... a hospital news release. "If you know you ...
(Date:11/22/2014)... 2014 Hastings and Hastings, a discount ... announces providing clients with the option of leaving an ... a flexible, intuitive and easy to navigate website that ... to Google + allows clients to research the Hastings ... more informed decision when retaining an attorney. Those who ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3
... the sleep disturbances, study finds , WEDNESDAY, Dec. 2 (HealthDay ... increase the risk of sleep apnea, say U.S. researchers. , ... damages the brain and can cause immediate and dangerous problems ... the Johns Hopkins School of Medicine in Baltimore, said in ...
... say , WEDNESDAY, Dec. 2 (HealthDay News) -- New research ... in the lives of people with Fabry disease, a rare ... The progressive disease, linked to the lack of an enzyme ... fatal because it boosts the risk for a stroke, heart ...
... 2 Huntington Memorial Hospital,s stroke program has received ... designating the hospital a primary stroke center. This ... center" hospitals throughout Los Angeles County. , ... more important, a wonderful benefit for Pasadena and its ...
... SAN FRANCISCO, Dec. 2 In the wake of the ... plastics chemical linked to birth defects and breast cancer, Congress ... House and Senate are considering bills to ban bisphenol A, ... Sen. Dianne Feinstein of California and Rep. Edward Markey of ...
... , ... , WASHINGTON, Dec. 2 The membership of the National Quality ... and reappointed four current Board members. The new Board members represent ... suppliers, and public and community healthcare. , The newly elected ...
... , NEW YORK, Dec. 2 Care ... Advanced Illness Coordinated Care (AICC) , has been shown to reduce ... the quality of life for seniors and their family caregivers without ... published in American Journal of Managed Care (November 2009). ...
Cached Medicine News:Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
(Date:11/21/2014)... 2014 In September 2014, the staff at ... a new product development plan that started with the ... lab coat , aptly named "Vera G.," after ... the world. The new women,s designer lab coat is ... sleek envelope collar, vertical princess and high waist seaming, ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... The challenge for Carl Zeiss was ... on the eye and for preoperative ... result of this development work is ... revolutionizing all previous techniques and setting ...
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
Medicine Products: